Abstract
ANCA vasculitides are a rare group of systemic inflammatory disorders for which infection is the leading cause of mortality. Rituximab is the only FDA-approved medication for induction and remission maintenance therapy in AAV. Patients treated with Rituximab often experience a decline in their immunoglobulin level for reasons that are poorly understood.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
